Trial Profile

A Randomized Clinical Trial of Andexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor Xa Inhibitor

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 16 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Andexanet alfa (Primary)
Indications Intracranial haemorrhages
Focus Registrational; Therapeutic Use
Acronyms ANNEXa-I
Sponsors Alexion AstraZeneca Rare Disease; Portola Pharmaceuticals

Most Recent Events

08 Jan 2024 This trial has been Discontinued in Finland, according to European Clinical Trials Database record.
05 Nov 2023 This trial has been completed in Poland, according to European Clinical Trials Database record.
11 Sep 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com